IMTX · Immatics N.V.
$9.08
+1.22% last session
End-of-day data · updated 2026-07-28
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-4.6
Dividend yield
—
Beta
1.32
Avg volume
0M
Employees
1K
2D change
—
5D change
-7.10%
10D change
-10.01%
30D change
-9.35%
60D change
-25.02%
MTD change
-12.39%
YTD change
-17.81%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IMTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-05-19
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-05-19 | Chardan Capital | Maintains | Buy | $25.00 |
| 2026-04-28 | TD Cowen | Initiates | Buy | $0.00 |
| 2025-11-24 | Chardan Capital | Maintains | Buy | $25.00 |
| 2025-11-19 | Mizuho | Maintains | Outperform | $19.00 → $23.00 |
| 2025-11-18 | Guggenheim | Maintains | Buy | $16.00 → $19.00 |
| 2025-09-18 | Guggenheim | Initiates | Buy | $0.00 → $16.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 37 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 12.2% below the 50-day MA ($9.95).
- Price vs 200-day MA: Trading 13.7% below the 200-day MA ($10.12).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-0.07) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($5.09) and high ($11.87).
IMTX Price Chart
Loading chart for IMTX…
Fundamentals
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.